AcelRx Pharmaceuticals (NASDAQ:ACRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

A number of other equities analysts have also recently weighed in on ACRX. ValuEngine raised AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Jefferies Group lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Royal Bank of Canada dropped their target price on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, October 13th. Piper Jaffray Companies reiterated a “hold” rating and issued a $2.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $6.21.

AcelRx Pharmaceuticals (ACRX) traded down $0.05 during midday trading on Tuesday, hitting $2.00. The stock had a trading volume of 221,100 shares, compared to its average volume of 382,036. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The firm has a market capitalization of $100.68, a PE ratio of -1.79 and a beta of 2.96. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). analysts forecast that AcelRx Pharmaceuticals will post -1.06 EPS for the current fiscal year.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now owns 150,000 shares of the company’s stock, valued at approximately $285,000. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 28.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Perennial Advisors LLC purchased a new stake in AcelRx Pharmaceuticals during the third quarter valued at about $138,000. Geller Family Office Services LLC purchased a new stake in shares of AcelRx Pharmaceuticals in the third quarter worth about $460,000. Virtu KCG Holdings LLC boosted its position in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of AcelRx Pharmaceuticals in the second quarter worth about $530,000. 13.60% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “AcelRx Pharmaceuticals (ACRX) Rating Lowered to Hold at Zacks Investment Research” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/01/23/acelrx-pharmaceuticals-acrx-rating-lowered-to-hold-at-zacks-investment-research.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.